PV is a life-threatening condition associated with increased mortality and reduced quality of life1,2

PV is a myeloproliferative neoplasm characterised by an increase in blood cell production.1,2 A mutation in the JAK2 gene leads to an overactive JAK/STAT pathway.1 The result is an elevated HCT value and increased risk of thromboembolic events and debilitating symptoms.2,3


Icon of the United Kingdom

In the UK, 2 people per 100,000 have PV4

the text 'greater than99%'

Of patients with PV have a JAK2 mutation1

the text '14 Years'

Median overall survival*1

the text '60 Years'

Median age at diagnosis5



Patients with PV have a high symptom burden that detrimentally impacts their lives1,2

Patients with PV may suffer from a wide range of symptoms that can impact their quality of life.2,6
Click each symptom to see how many patients with PV (n=538) reported being affected by it:†6

plus symbol

plus symbol

plus symbol

plus symbol
Night sweats

plus symbol
Weight loss


plus symbol

Early satiety

plus symbol


plus symbol

Bone pain

plus symbol


plus symbol


61% of patients report symptom reduction as their primary goal of treatment‡2


Patients can still be burdened by symptoms despite blood count control6

The prospective, observational REVEAL study of 1813 patients with PV showed that a moderately high symptom burden is present regardless of blood count control.7

Patients may not understand that any changes to how they are feeling, even while their blood counts are controlled, may be related to their PV. They can regularly track their symptoms using an online tracker to ensure they give you the full picture during each appointment.


Logo of PV tracker, the Novartis-funded MPN10 tracker

Help patients monitor their symptoms with the Novartis-funded MPN10 tracker – download here or copy and paste the link into your browser: https://www.mpntracker.com/en-GB

Discover more information about PV and how it impacts the people who live with it:



Hydroxyurea is synonymous with/refers to hydroxycarbamide throughout.

*Among 826 Mayo Clinic patients with ET, PV or PMF, the respective median survivals were approximately 20 years for ET, 14 years for PV and 6 years for PMF1
Data from self-reported symptom scores from patients with PV (n=538) in a study evaluating the MPN-SAF TSS tool (N=1433).6 The MPN-SAF TSS is calculated as the mean score for the 10 items shown here. Self-reported symptom severity was rated on a 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) scale. In this study, the MPN-SAF TSS for PV was calculated as mean 21.8 (SD 16.3).6
Data from patients with MPNs (ET, n=302; MF, n=174; PV, n=223) surveyed in the International MPN Landmark Survey (N=699).2

ET, essential thrombocythaemia; HCT, haematocrit; HU, hydroxyurea; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MPN-SAF TSS, Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score; PMF, primary myelofibrosis; PV, polycythaemia vera; SD, standard deviation.


  1. Tefferi A, Barbui T. Am J Hematol. 2020;95:1599–1613.
  2. Harrison CN, et al. Ann Hematol. 2017;96:1653–1665.
  3. Tefferi A, et al. Leukemia. 2021; 35:3339–3351.
  4. MPN Voice. Polycythaemia Vera. Available at: https://www.mpnvoice.org.uk/about-mpns/questions/polycythaemia-vera/. Last accessed July 2023.
  5. Lurlo A, et al. Int J Mol Sci. 2020;21:5805.
  6. Emanuel RM, et al. J Clin Oncol. 2012;30:4098–4041.
  7. Grunwald MR, et al. Clin Lymphoma Myeloma Leuk. 2019;19:579–584.
Rate this content: 
No votes yet
UK | July 2023 | 253137

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]